drugset
drugset / Trial / NCT02433158

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT02433158 ↗

Phase 3 Terminated 154 enrolled GlycoMimetics Incorporated
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).

Timeline

Start
2015-12-16
Primary completion
2019-11-15
Completion
2019-11-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivipansel Small molecule 20 mg/kg Intravenous
Subject Rivipansel Small molecule 840 mg Intravenous

Indications

sickle cell disease